Skip to content

    Heart Disease Health Center

    Font Size

    New Anticlotting Drug Beats Plavix

    Brilinta Increases Stent Patients' Survival in Large Clinical Trial
    WebMD Health News
    Reviewed by Louise Chang, MD

    Jan. 13, 2010 - A new anticlotting drug works better than Plavix, one of the most prescribed and most profitable drugs in the world, a huge clinical trial finds.

    The new kid on the block is AstraZeneca's ticagrelor, to be named Brilinta if the experimental drug gets FDA approval.

    That approval seems likely, given the results of a new clinical trial that compared Plavix to Brilinta in patients with acute coronary syndromes who had stents placed in their arteries to improve blood flow. Such patients need anticlotting drugs because blood clots can be a deadly complication of getting a stent.

    Plavix is the drug most often used to prevent this complication. But there's a problem with Plavix, and with a newer, stronger drug in the same class called Effient.

    Both drugs increase the risk of dangerous bleeding. And since the drugs irreversibly bind to blood-clotting platelets, a patient has to stop taking these drugs for five to seven days before the body can make enough new platelets.

    Brilinta lets go of platelets more quickly than Plavix -- in about two or three days. And in the new study, patients had less bleeding after stent installation.

    That's probably why the 6,732 study patients who got Brilinta were 16% less likely to die, or have a heart attack or stroke, than were the 6,676 patients who got Plavix. Brilinta reduced overall death rates by 1.1% .

    "We estimate that use of [Brilinta] instead of [Plavix] for one year in 1,000 patients with acute coronary syndromes and who are planning to undergo an invasive strategy at the start of drug treatment would lead to 11 fewer deaths, 13 fewer myocardial infarctions, and six fewer cases of stent [clotting] without an increase in the rates of major bleeding or transfusion," conclude study researcher Christopher P. Cannon, MD, and colleagues.

    The findings impress Columbia University researcher Gregg W. Stone, MD. Stone has in the past received honoraria from the makers of both Plavix and Brilinta and serves on the advisory boards of Boston Scientific and Abbott Vascular.

    Today on WebMD

    x-ray of human heart
    A visual guide.
    atrial fibrillation
    Symptoms and causes.
    heart rate graph
    10 things to never do.
    heart rate
    Get the facts.
    empty football helmet
    red wine
    eating blueberries
    Simple Steps to Lower Cholesterol
    Inside A Heart Attack
    Omega 3 Sources
    Salt Shockers
    lowering blood pressure